This is what happens to your hands and wrists when you type too much
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Nature3d
Bow Hunter's Syndrome and Vertebral Artery Disorders
Bow Hunter's Syndrome (BHS) is a rare condition characterized by vertebrobasilar insufficiency, which occurs when the vertebral artery is compressed during head rotation. This compression can lead ...
BioPharma Dive12d
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
The deal with Nippon Shinyaku announced Tuesday will hand over partial responsibility to Regenxbio’s most advanced wholly ...
Nasdaq17d
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
In 2021, the FDA granted Fast Track designation to tividenofusp alfa for the treatment of patients with Hunter syndrome ... Director of Research Sheraz Mian hand-picks one to have the most ...
FierceBiotech13d
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
North Texas teen offers hope to others with Hunter Syndrome
Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.
Yahoo Finance18d
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).